- Home
- PYPD vs SPAI Comparison
PYPD vs SPAI Comparison
Compare PYPD & SPAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- SPAI
- Stock Information
- Founded
- PYPD 2008
- SPAI 2021
- Country
- PYPD Israel
- SPAI United States
- Employees
- PYPD N/A
- SPAI N/A
- Industry
- PYPD Medical/Dental Instruments
- SPAI Industrial Specialties
- Sector
- PYPD Health Care
- SPAI Health Care
- Exchange
- PYPD Nasdaq
- SPAI Nasdaq
- Market Cap
- PYPD 35.3M
- SPAI 41.3M
- IPO Year
- PYPD 2020
- SPAI 2024
- Fundamental
- Price
- PYPD $3.58
- SPAI $2.54
- Analyst Decision
- PYPD Strong Buy
- SPAI
- Analyst Count
- PYPD 5
- SPAI 0
- Target Price
- PYPD $11.40
- SPAI N/A
- AVG Volume (30 Days)
- PYPD 1.4M
- SPAI 39.2K
- Earning Date
- PYPD 08-13-2025
- SPAI 08-15-2025
- Dividend Yield
- PYPD N/A
- SPAI N/A
- EPS Growth
- PYPD N/A
- SPAI N/A
- EPS
- PYPD N/A
- SPAI N/A
- Revenue
- PYPD N/A
- SPAI $2,046,327.00
- Revenue This Year
- PYPD N/A
- SPAI N/A
- Revenue Next Year
- PYPD N/A
- SPAI N/A
- P/E Ratio
- PYPD N/A
- SPAI N/A
- Revenue Growth
- PYPD N/A
- SPAI 140.22
- 52 Week Low
- PYPD $2.30
- SPAI $1.47
- 52 Week High
- PYPD $4.49
- SPAI $6.50
- Technical
- Relative Strength Index (RSI)
- PYPD 59.00
- SPAI N/A
- Support Level
- PYPD $3.12
- SPAI N/A
- Resistance Level
- PYPD $3.75
- SPAI N/A
- Average True Range (ATR)
- PYPD 0.29
- SPAI 0.00
- MACD
- PYPD 0.01
- SPAI 0.00
- Stochastic Oscillator
- PYPD 69.83
- SPAI 0.00
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About SPAI Safe Pro Group Inc. Common Stock
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.